standard statistics were used with a p value of <0.05 considered significant. RESULTS: There were 314 women identified, 178 (56.7%) with methadone use and 136 (43.3%) with buprenorphine use. Both groups were similar in maternal age, race, parity, homeless rate, tobacco use, mode of delivery and incidence of neonatal abstinence syndrome (NAS) OBJECTIVE: To explore the effects of gestational OMT on placental development STUDY DESIGN: This is a retrospective cohort study of pregnant patients on OMT (buprenorphine or methadone) between January 2007 and December 2017. ICD codes were used to identify OMT patients. The control group consisted of random non-drug users matched for GA. Patients were excluded if they had gestational diabetes, multiple gestations, positive meconium toxicology results for substances other than methadone or buprenorphine and those without microscopic placental evaluation. Placental weight and histologic evaluation were obtained and compared among the groups. Data analysis was performed using one-way ANOVA with pvalue <0.05 significant. RESULTS: 454 cases were reviewed; of which 109 met the inclusion criteria (66 patients were on methadone, 43 were on buprenorphine, and 40 were controls). Gestational age at birth and neonatal birth weight were significantly lower in the methadone group compared to the buprenorphine and control groups . The placenta to neonatal birth weight ratio was significantly higher in the methadone and buprenorphine groups compared to controls (p<0.01). There was no statistically significant difference between methadone and buprenorphine groups (mean AE standard deviation; methadone: 0.19 AE 0.03; buprenorphine: 0.18 AE 0.04; control: 0.15 AE 0.03).The rate ratio of placental dysmaturity (Figure 1 ) was significantly higher in the methadone and buprenorphine groups compared to control (rate ratio 3.8 and 3.7) CONCLUSION: Gestational OMT is associated with placentomegaly and placental dysmaturity compared to non-drug users. These findings are correlated with reduced surface area for oxygen diffusion, which may affect neonatal well-being. Further analysis is underway to evaluate the effects of placental dysmaturity on neonatal outcomes. OBJECTIVE: Neonates exposed to opioids in utero present a growing public health crisis in the US as the incidence of neonatal opioid withdrawal (NOW) has nearly tripled in the last two decades. Treatment of NOW can vary among hospitals thereby making it difficult to identify the most effective approach. Non-pharmacological management, such as parental presence, rooming-in, and breastfeeding, have been shown to decrease the severity of withdrawal. Studies suggest that infants with NOW who require pharmacologic treatment have lower cognitive scores. The objective of this study was to determine the optimal management strategy of NOW and its effects on neurodevelopmental outcomes.
314 Is opioid maintenance therapy (OMT) associated with placentomegaly and placental dysmaturity?
Cara Staszewski, Elizabeth Kertowidjojo, Victoria Ly, Diana Garretto, Cynthia Kaplan, David Garry, Malini Persad, Kimberly Herrera Stony Brook University Hospital, Stony Brook, NY OBJECTIVE: To explore the effects of gestational OMT on placental development STUDY DESIGN: This is a retrospective cohort study of pregnant patients on OMT (buprenorphine or methadone) between January 2007 and December 2017. ICD codes were used to identify OMT patients. The control group consisted of random non-drug users matched for GA. Patients were excluded if they had gestational diabetes, multiple gestations, positive meconium toxicology results for substances other than methadone or buprenorphine and those without microscopic placental evaluation. Placental weight and histologic evaluation were obtained and compared among the groups. Data analysis was performed using one-way ANOVA with pvalue <0.05 significant. RESULTS: 454 cases were reviewed; of which 109 met the inclusion criteria (66 patients were on methadone, 43 were on buprenorphine, and 40 were controls). Gestational age at birth and neonatal birth weight were significantly lower in the methadone group compared to the buprenorphine and control groups . The placenta to neonatal birth weight ratio was significantly higher in the methadone and buprenorphine groups compared to controls (p<0.01). There was no statistically significant difference between methadone and buprenorphine groups (mean AE standard deviation; methadone: 0.19 AE 0.03; buprenorphine: 0.18 AE 0.04; control: 0.15 AE 0.03).The rate ratio of placental dysmaturity (Figure 1 ) was significantly higher in the methadone and buprenorphine groups compared to control (rate ratio 3.8 and 3.7) CONCLUSION: Gestational OMT is associated with placentomegaly and placental dysmaturity compared to non-drug users. These findings are correlated with reduced surface area for oxygen diffusion, which may affect neonatal well-being. Further analysis is underway to evaluate the effects of placental dysmaturity on neonatal outcomes. OBJECTIVE: Neonates exposed to opioids in utero present a growing public health crisis in the US as the incidence of neonatal opioid withdrawal (NOW) has nearly tripled in the last two decades. Treatment of NOW can vary among hospitals thereby making it difficult to identify the most effective approach. Non-pharmacological management, such as parental presence, rooming-in, and breastfeeding, have been shown to decrease the severity of withdrawal. Studies suggest that infants with NOW who require pharmacologic treatment have lower cognitive scores. The objective of this study was to determine the optimal management strategy of NOW and its effects on neurodevelopmental outcomes.
Poster Session II STUDY DESIGN: A decision-analytic model was constructed using TreeAge to compare outcomes in infants affected by NOW. We used a theoretical cohort of 23,200 neonates (an estimate of the annual number of births affected by NOW in the US). The strategies compared are rooming-in versus not rooming-in and breastfeeding versus formula in evaluating the need for pharmacologic treatment. Primary outcomes were length of stay and neurodevelopment. We undertook a societal perspective over a lifetime, and all costs are expressed in 2018 US dollars. Effectiveness was based on combined maternal and neonatal quality-adjusted life years (QALYs). A costeffectiveness threshold was set at $100,000/QALY. All model inputs were derived from the literature and varied in sensitivity analyses to assess the robustness of the model. RESULTS: Rooming-in increased the likelihood of breastfeeding and resulted in fewer neonates requiring pharmacologic intervention. Rooming-in resulted in cost savings of $349,543,960 and 7,888 additional QALYs (Table) . When the probability of pharmacologic treatment was varied, rooming-in remained the dominant strategy with lower costs and increased effectiveness ( Figure) . CONCLUSION: Rooming-in with infants affected by NOW promotes breastfeeding and decreases the need for pharmacologic treatment thereby mitigating neurodevelopmental sequelae. Management strategies in this population should focus on optimizing non-pharmacologic interventions. OBJECTIVE: 24 states impose gestational-age limits on abortion, with 17 banning abortion at 20 weeks post-fertilization or its equivalent of 22 weeks LMP. Our objective was to characterize fetal indications for abortion at !22 weeks at our institution, and to compare indications for abortion in these women to those undergoing abortion earlier in the 2nd trimester. STUDY DESIGN: We identified patients receiving prenatal care at our institution from 2012-2017 who underwent abortion at !15 weeks' gestation. Medical record review identified clinical factors including indications for abortion. A fetal anomaly was categorized as "Genetic" if the genetic disorder was the initial diagnosis. If a major structural anomaly led to a genetic diagnosis, the structural anomaly was considered the initial diagnosis. Fisher's exact test and chi-square were used to compare those undergoing abortion !22 weeks vs. 15-21 weeks. RESULTS: 168 women underwent abortion for fetal indications at !15 weeks, with 64 (38%) at !22 weeks. Indications are in the Table. While genetic disorders were more common at 15-21 weeks (42% vs. 16% p<.001), CNS anomalies (30% vs. 12%; p¼.008) and IUGR (12% vs. 3%; p¼.02) were more common at !22 weeks. 50% of those with structural anomalies at 15-21 had ultrasound early in the 2nd trimester compared to only 7% in those undergoing abortion at !22 weeks (p<.001), with abnormal 1st-trimester ultrasound and high MSAFP the most common indications. In those diagnosed at routine anatomy scan, those undergoing abortion at !22 weeks were more likely to have this scan at >20.0 weeks (60 vs. 11%; p<.001). Genetic disorders in the 15-21 week group were more likely to be conditions screened for compared to those at !22 weeks (52% vs. 17%; p¼.005), and 3 of 4 common abnormalities in the !22 week group had false-negative screening. CONCLUSION: Abortions performed at !22 weeks for fetal indications were more likely to involve structural anomalies compared to those performed at 15-21 weeks, in whom genetic disorders were most common. Most genetic disorders in those undergoing earlier abortion were conditions routinely screened for. While improvements in genetic screening and referring high-risk patients for early 2nd trimester ultrasound can lead to earlier abortion, conditions in patients without risk factors may go unsuspected until late in the 2nd trimester. Earlier 2nd-trimester ultrasound may be necessary to expedite prenatal diagnosis if gestational age limitations on abortion are enforced. OBJECTIVE: The objective of this study was to characterize the risk for severe maternal morbidity by maternal age during delivery hospitalizations for twin pregnancies. STUDY DESIGN: This retrospective cohort study utilized the Nationwide Inpatient Sample (NIS) from the Agency for Healthcare Research and Quality for the years 1998 to 2014. Women aged 15 to 54 hospitalized for delivery with a diagnosis of a twin pregnancy were included. Age was categorized as 15-17, 18-24, 25-29, 30-34, 35-39, 40-44, and 45-54 years. The overall risk for severe morbidity (SMM) based on Centers for Disease Control and Prevention criteria was analyzed stratified by maternal age, along with the risk for specific outcomes including disseminated intravascular coagulation (DIC) and hysterectomy. SMM was assessed with and without transfusion. Log-linear models were created to assess the risk for
